Sanguinarine mediated apoptosis in Non-Small Cell Lung Cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 08 08 2021
revised: 08 10 2021
accepted: 19 10 2021
entrez: 19 11 2021
pubmed: 20 11 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Effective treatment of lung cancer remains a significant clinical challenge due to its multidrug resistance and side effects of the current treatment options. The high mortality associated with this malignancy indicates the need for new therapeutic interventions with fewer side effects. Natural compounds offer various benefits such as easy access, minimal side effects, and multi-molecular targets and thus, can prove useful in treating lung cancer. Sanguinarine (SNG), a natural compound, possesses favorable therapeutic potential against a variety of cancers. Here, we examined the underlying molecular mechanisms of SNG in Non-Small Cell Lung Cancer (NSCLC) cells. SNG suppressed cell growth and induced apoptosis via downregulation of the constitutively active JAK/STAT pathway in all the NSCLC cell lines. siRNA silencing of STAT3 in NSCLC cells further confirmed the involvement of the JAK/STAT signaling cascade. SNG treatment increased Bax/Bcl-2 ratio, which contributed to a leaky mitochondrial membrane leading to cytochrome c release accompanied by caspase activation. In addition, we established the antitumor effects of SNG through reactive oxygen species (ROS) production, as inhibiting ROS production prevented the apoptosis-inducing potential of SNG. In vivo xenograft tumor model further validated our in vitro findings. Overall, our study investigated the molecular mechanisms by which SNG induces apoptosis in NSCLC, providing avenues for developing novel natural compound-based cancer therapies.

Identifiants

pubmed: 34794241
pii: S0753-3322(21)01142-2
doi: 10.1016/j.biopha.2021.112358
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Benzophenanthridines 0
Isoquinolines 0
RNA, Small Interfering 0
Reactive Oxygen Species 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
sanguinarine AV9VK043SS
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112358

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Kirti S Prabhu (KS)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Ajaz A Bhat (AA)

Molecular and Metabolic Imaging Laboratory, Cancer Research Department, Sidra Medicine, Qatar.

Kodappully S Siveen (KS)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Shilpa Kuttikrishnan (S)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Syed Shadab Raza (SS)

Department of Stem Cell Biology and Regenerative Medicine, Era University, Lucknow 226003, India.

Thesni Raheed (T)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Anh Jochebeth (A)

Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.

Abdul Q Khan (AQ)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

M Zafar Chawdhery (MZ)

Surgery Department, St. Anthony's Hospital, Surrey SM3 9DW, UK.

Mohammad Haris (M)

Molecular and Metabolic Imaging Laboratory, Cancer Research Department, Sidra Medicine, Qatar; Laboratory Animal Research Center, Qatar University, Doha, Qatar.

Michal Kulinski (M)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.

Said Dermime (S)

National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Martin Steinhoff (M)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar; Department of Dermatology, Weill Cornell Medicine, Qatar Foundation, Education City, Doha, Qatar; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Shahab Uddin (S)

Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar; Laboratory Animal Research Center, Qatar University, Doha, Qatar. Electronic address: SKhan34@hamad.qa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH